FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4293113495> ?p ?o ?g. }

• W4293113495 endingPage "194" @default.
• W4293113495 startingPage "190" @default.
• W4293113495 abstract "Background: Combining palbociclib with letrozole or fulvestrant improved progression-free survival in hormone receptor (HR)-positive and human epidermal growth factor receptor-negative metastatic breast cancer. However, combining palbociclib to endocrine treatment increases toxicity and cost compared with the endocrine treatment alone. Moreover, palbociclib treatment may affect the outcome of the subsequent treatment because its benefit in terms of overall survival has not been observed yet. Therefore, it is crucial to examine whether palbociclib can improve clinical outcomes and quality of life (QoL) of patients in the real world. Methods: A prospective observational study with palbociclib is planned in 3 cohorts (A, B, and C) as per the line of endocrine treatment (i.e., first-line, second-line, or third-line or later-line treatment) for postmenopausal metastatic or unresectable breast cancer. The primary endpoint is progression-free survival in each treatment line, the most commonly used endpoint for global phase 3 studies. As per the results of these studies, the planned sample size is 700 cases: cohort A, 340 cases; cohort B, 200 cases; and cohort C, 130 cases. The secondary endpoints are overall survival, clinical benefit rate, time to chemotherapy, adverse events (AEs), patient-reported outcomes (PROs), and health-related QoL (HRQoL). These endpoints are evaluated again during the subsequent treatment. This study will examine whether the efficacy, safety, and QoL effects of palbociclib treatment in daily clinical practice are not inferior compared to those in clinical trials and whether palbociclib treatment affects the efficacy and safety of the subsequent treatment. Moreover, this study would provide information on the most effective time of adding palbociclib to endocrine treatment. Discussion: The reproducibility of randomized clinical trials (RCTs) using real-world data must be confirmed to evaluate whether real-world treatment benefits are similar to those observed in RCTs. Although the efficacy of palbociclib has been confirmed in RCTs, Aes of this drug, including its toxicities and cost, are not comparable to those of mono-hormone therapies. Thus, PROs/HRQoL is an important element of this study because several patients with HR-positive metastatic breast cancer have diseases for which sequential hormone therapy is preferential. World J Oncol. 2022;13(4):190-194 doi: https://doi.org/10.14740/wjon1507" @default.
• W4293113495 created "2022-08-26" @default.
• W4293113495 creator A5007957984 @default.
• W4293113495 creator A5028664306 @default.
• W4293113495 creator A5065550886 @default.
• W4293113495 creator A5087348287 @default.
• W4293113495 creator A5089829213 @default.
• W4293113495 date "2022-08-01" @default.
• W4293113495 modified "2023-10-18" @default.
• W4293113495 title "Prospective Cohort Study of Palbociclib Treatment in Postmenopausal Patients With Unresectable and Metastatic Hormone Receptor-Positive Breast Cancer: Study Protocol for a CSPOR-BC Palbociclib Cohort Trial" @default.
• W4293113495 cites W1988231505 @default.
• W4293113495 cites W2144790402 @default.
• W4293113495 cites W2145238269 @default.
• W4293113495 cites W2255638054 @default.
• W4293113495 cites W2290950904 @default.
• W4293113495 cites W2552099557 @default.
• W4293113495 cites W2791840917 @default.
• W4293113495 cites W2802484510 @default.
• W4293113495 cites W2896846857 @default.
• W4293113495 cites W2898684787 @default.
• W4293113495 cites W2901270440 @default.
• W4293113495 cites W2924345863 @default.
• W4293113495 cites W3016055296 @default.
• W4293113495 cites W4234050115 @default.
• W4293113495 doi "https://doi.org/10.14740/wjon1507" @default.
• W4293113495 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36128589" @default.
• W4293113495 hasPublicationYear "2022" @default.
• W4293113495 type Work @default.
• W4293113495 citedByCount "2" @default.
• W4293113495 countsByYear W42931134952023 @default.
• W4293113495 crossrefType "journal-article" @default.
• W4293113495 hasAuthorship W4293113495A5007957984 @default.
• W4293113495 hasAuthorship W4293113495A5028664306 @default.
• W4293113495 hasAuthorship W4293113495A5065550886 @default.
• W4293113495 hasAuthorship W4293113495A5087348287 @default.
• W4293113495 hasAuthorship W4293113495A5089829213 @default.
• W4293113495 hasBestOaLocation W42931134951 @default.
• W4293113495 hasConcept C121608353 @default.
• W4293113495 hasConcept C126322002 @default.
• W4293113495 hasConcept C143998085 @default.
• W4293113495 hasConcept C159110408 @default.
• W4293113495 hasConcept C188816634 @default.
• W4293113495 hasConcept C197934379 @default.
• W4293113495 hasConcept C203092338 @default.
• W4293113495 hasConcept C2775930923 @default.
• W4293113495 hasConcept C2777176818 @default.
• W4293113495 hasConcept C2778812593 @default.
• W4293113495 hasConcept C2779744173 @default.
• W4293113495 hasConcept C2779951463 @default.
• W4293113495 hasConcept C2780482068 @default.
• W4293113495 hasConcept C530470458 @default.
• W4293113495 hasConcept C535046627 @default.
• W4293113495 hasConcept C71924100 @default.
• W4293113495 hasConcept C72563966 @default.
• W4293113495 hasConcept C84606932 @default.
• W4293113495 hasConceptScore W4293113495C121608353 @default.
• W4293113495 hasConceptScore W4293113495C126322002 @default.
• W4293113495 hasConceptScore W4293113495C143998085 @default.
• W4293113495 hasConceptScore W4293113495C159110408 @default.
• W4293113495 hasConceptScore W4293113495C188816634 @default.
• W4293113495 hasConceptScore W4293113495C197934379 @default.
• W4293113495 hasConceptScore W4293113495C203092338 @default.
• W4293113495 hasConceptScore W4293113495C2775930923 @default.
• W4293113495 hasConceptScore W4293113495C2777176818 @default.
• W4293113495 hasConceptScore W4293113495C2778812593 @default.
• W4293113495 hasConceptScore W4293113495C2779744173 @default.
• W4293113495 hasConceptScore W4293113495C2779951463 @default.
• W4293113495 hasConceptScore W4293113495C2780482068 @default.
• W4293113495 hasConceptScore W4293113495C530470458 @default.
• W4293113495 hasConceptScore W4293113495C535046627 @default.
• W4293113495 hasConceptScore W4293113495C71924100 @default.
• W4293113495 hasConceptScore W4293113495C72563966 @default.
• W4293113495 hasConceptScore W4293113495C84606932 @default.
• W4293113495 hasIssue "4" @default.
• W4293113495 hasLocation W42931134951 @default.
• W4293113495 hasLocation W42931134952 @default.
• W4293113495 hasLocation W42931134953 @default.
• W4293113495 hasOpenAccess W4293113495 @default.
• W4293113495 hasPrimaryLocation W42931134951 @default.
• W4293113495 hasRelatedWork W2740803632 @default.
• W4293113495 hasRelatedWork W2751810360 @default.
• W4293113495 hasRelatedWork W2892008472 @default.
• W4293113495 hasRelatedWork W2931385471 @default.
• W4293113495 hasRelatedWork W2943438364 @default.
• W4293113495 hasRelatedWork W3031130887 @default.
• W4293113495 hasRelatedWork W3203106735 @default.
• W4293113495 hasRelatedWork W3203690439 @default.
• W4293113495 hasRelatedWork W4226356606 @default.
• W4293113495 hasRelatedWork W4282924254 @default.
• W4293113495 hasVolume "13" @default.
• W4293113495 isParatext "false" @default.
• W4293113495 isRetracted "false" @default.
• W4293113495 workType "article" @default.